Intra-Cellular Therapies Sees 2024 CAPLYTA Net Product Sales $645M-$675M
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies projects its 2024 CAPLYTA net product sales to be between $645 million and $675 million.
February 22, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies expects its CAPLYTA net product sales for 2024 to range from $645 million to $675 million.
The projection of significant revenue from CAPLYTA sales in 2024 indicates strong performance and potential growth for Intra-Cellular Therapies. This positive outlook is likely to influence investor sentiment positively, potentially leading to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100